Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. (symbol: NDRA), is revolutionizing the field of ultrasound with its groundbreaking photo-acoustic solutions. The company’s innovations enable medical researchers to screen and modify disease models with unmatched quality and speed. ENDRA Life Sciences has established a global installed base of top-tier institutions utilizing their Nexus-128 system, the only comprehensive 3D imaging solution designed for imaging anatomy, physiology, and labeled molecular targets.
The Nexus 128 is a sophisticated preclinical photoacoustic computed tomography (CT) scanner tailored for small animal imaging. It facilitates quick, non-invasive quantification of physiological parameters, such as tumor vasculature, without the need for ionizing radiation. The fully 3D imaging technology of the Nexus 128 enhances sensitivity compared to traditional slice-based scanners, and its dynamic (4D) photoacoustic CT scans support advanced applications like quantification of probe uptake. Currently, leading imaging laboratories worldwide leverage the Nexus 128 for various research purposes.
Additionally, ENDRA Life Sciences is developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to visualize tissue with MRI-like clarity but at a fraction of the cost and at the point of patient care. The TAEUS technology is designed to integrate with approximately 400,000 cart-based ultrasound systems in use globally. Initially, TAEUS focuses on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions affecting over a billion people worldwide, for which there are currently no effective diagnostic tools. Beyond liver applications, TAEUS is also being explored for several other clinical uses, such as visualizing tissue temperature during energy-based surgical procedures.
ENDRA Life Sciences continues to push the boundaries of medical imaging technology, collaborating with various partners to further enhance their solutions. Stay updated with the latest achievements, projects, and news from ENDRA Life Sciences to understand their impact and progression in the medical technology landscape.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report its second quarter 2022 financial results on August 15, 2022, after market close. A conference call will follow at 4:30 p.m. Eastern time to discuss results and recent developments. Participants can pre-register for immediate access or dial in directly. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, aimed at visualizing tissue efficiently and cost-effectively, focusing initially on liver fat assessment related to NAFLD and NASH.
ENDRA Life Sciences (NASDAQ: NDRA) announces the issuance of three new patents by the U.S. Patent & Trademark Office, expanding its intellectual property portfolio to a total of 53 patents globally, including 31 in the U.S. The newly granted patents focus on methods for exchanging equipment performance data, significantly enhancing ENDRA’s technology for cloud-based data management. This provides potential licensing opportunities with other equipment manufacturers, especially in the medical imaging industry, and strengthens the company's competitive position.
ENDRA Life Sciences (NASDAQ: NDRA) will participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15-16, 2022. The management team will conduct one-on-one virtual meetings with investors. Interested participants can reach out to Needham or Yvonne Briggs at LHA for meeting requests. ENDRA is known for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization, primarily targeting liver conditions like NAFLD and NASH. This technology integrates with existing ultrasound systems worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents in China, extending its intellectual property protection for its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology through 2040. The newly granted patents, titled 'Systems and Methods for Thermoacoustic Transducer Optimization' and 'Method and System for Reconstructing a Thermoacoustic Image', enhance ENDRA's patent portfolio to 50 globally. This innovation targets Non-Alcoholic Fatty Liver Disease (NAFLD) and is aimed at the Chinese market, which is home to approximately 350 million affected individuals.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced the issuance of U.S. Patent No. 11369272, which protects its Thermo Acoustic Enhanced UltraSound (TAEUS) technology's radiofrequency (RF) applicator. This patent enhances optimization in RF energy delivery to tissues, minimizing sensitivity to tissue variations. ENDRA's patent portfolio now includes 48 patents globally. The company aims to broaden TAEUS applications in unmet clinical needs. TAEUS is designed for cost-effective imaging, initially targeting liver conditions affecting over one billion people worldwide.
ENDRA Life Sciences (NASDAQ: NDRA), a leader in enhanced ultrasound technology, will present at the JMP Securities Life Sciences Conference in New York City on June 15-16, 2022. The company's overview is scheduled for June 15 at 2:30 PM Eastern time, with additional one-on-one investor meetings available. ENDRA's innovative TAEUS® technology offers MRI-like tissue visualization at 1/50th the cost. Initially targeting Non-Alcoholic Fatty Liver Disease, it has broader applications, including tissue temperature monitoring during surgical procedures.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of U.S. Patent No. 11337676, protecting its method for optimizing radiofrequency energy delivery using Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent marks the 27th issued in the U.S. and contributes to ENDRA's strategy of advancing hybrid ultrasound imaging systems. Currently, ENDRA holds 90 IP assets globally and aims to address unmet clinical needs, primarily targeting Non-Alcoholic Fatty Liver Disease (NAFLD) and other applications.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami Beach. The company focuses on enhanced ultrasound technologies through its innovative TAEUS® system, which aims to visualize tissue akin to MRI at a significantly lower cost. This technology is especially relevant for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and other liver conditions affecting over one billion individuals globally. The presentation will be available on-demand starting May 24, 2022.
ENDRA Life Sciences (NASDAQ: NDRA) announced financial results for Q1 2022, reporting a net loss of $2.9 million, or $0.07 per share, compared to a net loss of $2.3 million, or $0.06 per share, in Q1 2021. The company raised $8.7 million in gross proceeds, extending its cash runway. ENDRA clarified its U.S. regulatory strategy for its TAEUS Liver System, targeting a De Novo submission in Q3 2022. Additionally, it expanded into China with a new clinical partner, grew its IP portfolio to 90 assets, and received ISO 13485:2016 recertification, enhancing its operational credibility.
ENDRA Life Sciences (NASDAQ: NDRA) has announced the issuance of four new patents, augmenting its global patent portfolio to 90 assets, including 46 issued patents. Two patents were issued in the U.S. and two in China, further protecting the TAEUS® system, which utilizes hybrid ultrasound and thermoacoustic imaging technology. Notably, one U.S. patent allows data transfer without an internet connection, paving the way for potential licensing opportunities in data management. This innovation not only strengthens ENDRA’s proprietary position but also presents new revenue generation avenues.
FAQ
What is the current stock price of ENDRA Life Sciences (NDRA)?
What is the market cap of ENDRA Life Sciences (NDRA)?
What does ENDRA Life Sciences Inc. specialize in?
What is the Nexus-128 system?
What are the applications of the TAEUS technology?
Who uses the Nexus-128 system?
How does the Nexus-128 system benefit medical research?
What are NAFLD and NASH?
How is TAEUS technology integrated into existing ultrasound systems?
What makes ENDRA's imaging technology unique?
Are there other clinical applications for TAEUS technology?
Where can I find the latest news and updates about ENDRA Life Sciences?
